Patents by Inventor Jan Tavernier

Jan Tavernier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF
    Publication number: 20210403525
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Lennart ZABEAU
  • TARGETED THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20210388088
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 16, 2021
    Inventors: Jan TAVERNIER, Nikolai KLEY
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • TARGETING OF HUMAN INTERFERON ANTAGONISTS
    Publication number: 20210238247
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: February 9, 2021
    Publication date: August 5, 2021
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
    Publication number: 20210238264
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 5, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Anje CAUWELS
  • TARGETED ENGINEERED INTERFERON AND USES THEREOF
    Publication number: 20210230291
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: December 24, 2020
    Publication date: July 29, 2021
    Inventors: Nikolai KLEY, Lennart ZABEAU, Jan TAVERNIER
  • Membrane span-kinase fusion protein and the uses thereof
    Patent number: 11053300
    Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 6, 2021
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Samuel Lievens
  • TARGETED HUMAN-INTERFERON FUSION PROTEINS
    Publication number: 20210162010
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Inventors: Jan TAVERNIER, Gilles UZÉ, Guillaume CARTRON, Franciane PAUL, Jacob PIEHLER
  • BISPECIFIC SIGNALING AGENTS AND USES THEREOF
    Publication number: 20210139586
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Application
    Filed: December 21, 2020
    Publication date: May 13, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Sandra VAN LINT, Anje CAUWELS
  • Clec9A binding agents
    Patent number: 11001631
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 11, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
  • Bispecific signaling agents and uses thereof
    Patent number: 10988538
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: April 27, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Sandra Van Lint, Anje Cauwels
  • Targeting of human interferon antagonists
    Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeted and mutated human-interferon fusion proteins
    Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Targeted engineered interferon and uses thereof
    Patent number: 10906985
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 2, 2021
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Lennart Zabeau, Jan Tavernier
  • CLEC9A BINDING AGENTS AND USE THEREOF
    Publication number: 20210024637
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF
    Publication number: 20210024631
    Abstract: The present invention relates, in part, to Fc-based chimeric protein complexes and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Fc-based chimeric protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • FIBROBLAST BINDING AGENTS AND USE THEREOF
    Publication number: 20210023167
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: February 5, 2019
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS
  • PD-1 AND PD-L1 BINDING AGENTS
    Publication number: 20200407448
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 31, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • XCR1 BINDING AGENTS AND USES THEREOF
    Publication number: 20200354424
    Abstract: The present invention relates, in part, to agents that bind XCR1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the XCR1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: January 28, 2019
    Publication date: November 12, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER
  • THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
    Publication number: 20200308244
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: Orionis Biosciences BV
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER